Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., reported fourth quarter financial results, including $4.3 million in gross revenues for Neudexta (dextromethorphan HBr and quinidine sulfate) and a cash burn of $14 million. The company reported cash and equivalents of $81.8 million as of Sept. 30. Net revenue for the fiscal year ending Sept. 30, was $10.5 million compared with $2.9 million for the same period in 2010.
